Matthew T. Chang
Matthew T. Chang
Loxo Oncology at Lilly
Verified email at loxooncology.com
Title
Cited by
Cited by
Year
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
16542017
The molecular taxonomy of primary prostate cancer
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
15612015
Genetic effects on gene expression across human tissues
GTE Consortium
Nature 550 (7675), 204-213, 2017
1513*2017
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
8312017
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
MT Chang, S Asthana, SP Gao, BH Lee, JS Chapman, C Kandoth, JJ Gao, ...
Nature biotechnology 34 (2), 155-163, 2016
4842016
Integrative analysis identifies four molecular and clinical subsets in uveal melanoma
AG Robertson, J Shih, C Yau, EA Gibb, J Oba, KL Mungall, JM Hess, ...
Cancer cell 32 (2), 204-220. e15, 2017
4152017
Comprehensive and integrated genomic characterization of adult soft tissue sarcomas
AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ...
Cell 171 (4), 950-965, 2017
3982017
Pathogenic germline variants in 10,389 adult cancers
K Huang, RJ Mashl, Y Wu, DI Ritter, J Wang, C Oh, M Paczkowska, ...
Cell 173 (2), 355-370. e14, 2018
3402018
Comprehensive molecular characterization of pheochromocytoma and paraganglioma
L Fishbein, I Leshchiner, V Walter, L Danilova, AG Robertson, ...
Cancer cell 31 (2), 181-193, 2017
3372017
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
3202018
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
3002017
Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines
K Ellrott, MH Bailey, G Saksena, KR Covington, C Kandoth, C Stewart, ...
Cell systems 6 (3), 271-281. e7, 2018
2862018
A comprehensive pan-cancer molecular study of gynecologic and breast cancers
AC Berger, A Korkut, RS Kanchi, AM Hegde, W Lenoir, W Liu, Y Liu, ...
Cancer cell 33 (4), 690-705. e9, 2018
2612018
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ...
Nature 548 (7666), 234-238, 2017
2542017
Copy number alteration burden predicts prostate cancer relapse
H Hieronymus, N Schultz, A Gopalan, BS Carver, MT Chang, Y Xiao, ...
Proceedings of the National Academy of Sciences 111 (30), 11139-11144, 2014
2522014
lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer
Z Wang, B Yang, M Zhang, W Guo, Z Wu, Y Wang, L Jia, S Li, ...
Cancer cell 33 (4), 706-720. e9, 2018
2502018
Genome doubling shapes the evolution and prognosis of advanced cancers
CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ...
Nature genetics 50 (8), 1189-1195, 2018
1872018
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
1862017
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
AR Moore, E Ceraudo, JJ Sher, Y Guan, AN Shoushtari, MT Chang, ...
Nature genetics 48 (6), 675-680, 2016
1812016
Accelerating discovery of functional mutant alleles in cancer
MT Chang, TS Bhattarai, AM Schram, CM Bielski, MTA Donoghue, ...
Cancer discovery, 2018
1522018
The system can't perform the operation now. Try again later.
Articles 1–20